Shows that Kynamro can't compete and Juxtapid is the treatment of choice.
The EU rejection of Kynamro was very telling. The risk of hepatic toxicity combined with its lower efficacy make Kynamro a very unlikely choice for physicians.
Contrast this with Juxtapids higher efficacy rate and lower instance of hepatic toxicity makes Juxtapid the better choice.
This is why insurance carriers authorize Juxtapid in 12-month increments compared with Kynamro's initial authorization for only 7-months. I surfers know Juxtapid works, but require early proof that the patient is responding to Kynamro before re-authorizing a 12-month treatment.